Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 17.02% is 39% above its 5-year average of 12.26%, near the high end of its 5-year range (-16.74%–21.46%).
0.04% above its 12-month average of 17.01%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 16.30%.
NET PROFIT MARGIN
17.02%
NET PROFIT MARGIN AVG TTM
17.01%
NET PROFIT MARGIN AVG 3Y
15.01%
NET PROFIT MARGIN AVG 5Y
12.26%
NET PROFIT MARGIN AVG 10Y
11.41%
NET PROFIT MARGIN AVG 15Y
12.29%
NET PROFIT MARGIN AVG 20Y
15.13%
CURRENT VS TTM AVG
+0.04%
CURRENT VS 3Y AVG
+13.42%
CURRENT VS 5Y AVG
+38.85%
CURRENT VS 10Y AVG
+49.20%
CURRENT VS 15Y AVG
+38.48%
CURRENT VS 20Y AVG
+12.52%
SECTOR MEDIAN · HEALTHCARE
9.21%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+84.90%
vs the sector median at left
AstraZeneca PLC
Market Cap
$248.50B
Net Profit Margin
17.02%
TTM Avg
17.01%
3Y Avg
15.01%
5Y Avg
12.26%
Market Cap
$224.13B
Net Profit Margin
15.06%
TTM Avg
14.95%
3Y Avg
14.84%
5Y Avg
16.47%
Market Cap
$197.12B
Net Profit Margin
35.33%
TTM Avg
33.96%
3Y Avg
33.83%
5Y Avg
33.74%
Market Cap
$179.83B
Net Profit Margin
-10.64%
TTM Avg
15.29%
3Y Avg
17.07%
5Y Avg
15.27%
Market Cap
$179.68B
Net Profit Margin
11.65%
TTM Avg
23.34%
3Y Avg
19.20%
5Y Avg
17.71%
Market Cap
$338.62B
Net Profit Margin
20.33%
TTM Avg
16.80%
3Y Avg
17.87%
5Y Avg
19.70%
Market Cap
$355.08B
Net Profit Margin
3.14%
TTM Avg
3.15%
3Y Avg
4.63%
5Y Avg
5.09%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $248.50B | 17.02% | 17.01% | 15.01% | 12.26% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.13B | 15.06% | 14.95% | 14.84% | 16.47% |
| Amgen Inc. (AMGN)vs › | $206.27B | 22.93% | 16.61% | 20.49% | 22.20% |
| Novo Nordisk A/S (NVO)vs › | $197.12B | 35.33% | 33.96% | 33.83% | 33.74% |
| Gilead Sciences, Inc. (GILD)vs › | $179.83B | -10.64% | 15.29% | 17.07% | 15.27% |
| Abbott Laboratories (ABT)vs › | $179.68B | 11.65% | 23.34% | 19.20% | 17.71% |
| Roche Holding AG (RHHBY)vs › | $338.62B | 20.33% | 16.80% | 17.87% | 19.70% |
| Pfizer Inc. (PFE)vs › | $156.67B | 6.81% | 12.51% | 14.97% | 18.18% |
| UnitedHealth Group Incorporated (UNH)vs › | $355.08B | 3.14% | 3.15% | 4.63% | 5.09% |
| Danaher Corporation (DHR)vs › | $141.50B | 15.95% | 15.52% | 19.51% | 19.37% |
Operating Margin
22.8%
Net Profit Margin
17.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 16.30% |
| 2026-03-31 | 20.15% |
| 2025-12-31 | 15.00% |
| 2025-09-30 | 16.67% |
| 2025-06-30 | 16.95% |
| 2025-03-30 | 21.46% |
| 2024-12-31 | 10.07% |
| 2024-09-30 | 10.53% |
| 2024-06-30 | 14.89% |
| 2024-03-31 | 17.19% |
| 2023-12-31 | 7.98% |
| 2023-09-30 | 11.96% |
| 2023-06-30 | 15.93% |
| 2023-03-31 | 16.57% |
| 2022-12-31 | 8.04% |
| 2022-09-30 | 14.93% |
| 2022-06-30 | 3.34% |
| 2022-03-31 | 3.39% |
| 2021-12-31 | -2.89% |
| 2021-09-30 | -16.74% |
| 2021-06-30 | 6.69% |
| 2021-03-31 | 21.33% |
| 2020-12-31 | 13.66% |
| 2020-09-30 | 9.85% |
| 2020-06-30 | 12.05% |
| 2020-03-31 | 12.28% |
| 2019-12-31 | 4.70% |
| 2019-09-30 | 4.67% |
| 2019-06-30 | 2.23% |
| 2019-03-31 | 10.80% |
| 2018-12-31 | 16.11% |
| 2018-09-30 | 8.07% |
| 2018-06-30 | 6.79% |
| 2018-03-31 | 6.57% |
| 2017-12-31 | 22.52% |
| 2017-09-30 | 11.01% |
| 2017-06-30 | 9.44% |
| 2017-03-31 | 9.94% |
| 2016-12-31 | 32.98% |
| 2016-09-30 | 17.79% |
| 2016-06-30 | -0.05% |
| 2016-03-31 | 10.56% |
| 2015-12-31 | 12.63% |
| 2015-09-30 | 12.95% |
| 2015-06-30 | 11.05% |
| 2015-03-31 | 9.08% |
| 2014-12-31 | -4.80% |
| 2014-09-30 | 3.84% |
| 2014-06-30 | 11.77% |
| 2014-03-31 | 7.80% |
| 2013-12-31 | -7.66% |
| 2013-09-30 | 19.94% |
| 2013-06-30 | 13.21% |
| 2013-03-31 | 15.83% |
| 2012-12-31 | 20.89% |
| 2012-09-30 | 22.61% |
| 2012-06-30 | 23.98% |
| 2012-03-31 | 22.11% |
| 2011-12-31 | 17.17% |
| 2011-09-30 | 42.34% |
| 2011-06-30 | 25.07% |
| 2011-03-31 | 35.06% |
| 2010-12-31 | 18.81% |
| 2010-09-30 | 19.60% |
| 2010-06-30 | 25.76% |
| 2010-03-31 | 32.38% |
| 2009-12-31 | 17.36% |
| 2009-09-30 | 25.79% |
| 2009-06-30 | 21.45% |
| 2009-03-31 | 27.87% |
| 2008-12-31 | 15.23% |
| 2008-09-30 | 22.25% |
| 2008-06-30 | 20.36% |
| 2008-03-31 | 19.58% |
| 2007-12-31 | 15.50% |
| 2007-09-30 | 18.78% |
| 2007-06-30 | 19.61% |
| 2007-03-31 | 22.39% |
| 2006-12-31 | 20.02% |
| 2006-09-30 | 24.36% |
| 2006-06-30 | 24.14% |
| 2006-03-31 | 23.04% |
| 2005-12-31 | 19.47% |
| 2005-09-30 | 21.13% |
| 2005-06-30 | 19.88% |
| 2005-03-31 | 18.11% |
| 2004-12-31 | 18.49% |
| 2004-09-30 | 21.52% |
| 2004-06-30 | 15.34% |
| 2004-03-31 | 15.71% |
| 2003-12-31 | 13.03% |
| 2003-09-30 | 16.71% |
| 2003-06-30 | 15.02% |
| 2003-03-31 | 19.68% |
| 2002-12-31 | 9.19% |
| 2002-09-30 | 15.45% |
